What Diagnostic Laboratory Services does

Diagnostic Laboratory Services, Inc. (DLS), founded in 1986 and headquartered in Hawaii, is the largest locally owned clinical and anatomic pathology laboratory in the state, operating 50+ Patient Service Centers across Hawaii, Guam, and Saipan with a workforce of more than 1,000 employees. The company delivers a broad diagnostic testing portfolio including clinical chemistry, anatomic pathology, microbiology, molecular diagnostics (PCR, qPCR), toxicology and drug testing (including DOT-compliant workplace drug screening and the Veri-5 confirmation system), and advanced precision-medicine services such as Next Generation Sequencing (NGS)-based tumor profiling, Homologous Recombination Deficiency (HRD) testing, Sanger Sequencing, microarray, fragment analysis, and nucleic acid extraction. DLS participates in the NCI-funded ComboMATCH program, connecting Hawaii cancer patients to national clinical trials matched to their tumor's genetics, and contributes NGS data to the Friends of Cancer Research HRD Harmonization project.

DLS operates through three primary channels: (1) walk-in Patient Service Centers serving patients with doctor's orders, supported by the myDLSchart web portal and iOS/Android mobile app; (2) onsite hospital laboratory operations under multi-year partnerships with Hawaii Health Systems Corporation (HHSC) facilities including Kona Community Hospital, Kohala Hospital, Kaua'i Veterans Memorial Hospital, and Samuel Mahelona Memorial Hospital, integrated with Epic EMR; and (3) physician-facing digital ordering via the eLabOrders desktop portal and DLS MD Portal mobile app. Revenue is generated through billed laboratory testing services paid by insurance, Medicare, Medicaid, and direct patient payment, with no publicly disclosed pricing.

The company is privately held with no parent company, institutional investor, or public listing evidenced. It has been recognized by Hawaii Business Magazine as one of the state's Best Places to Work for six consecutive years (2021–2026), and President Mark Wasielewski was named to the publication's '20 for the Next 20' leaders list in 2022. The wholly-owned subsidiary Hawaii Pathologists' Laboratory operates as the anatomic pathology sub-brand.

Name

Diagnostic Laboratory Services

Legal name

Diagnostic Laboratory Services, Inc.

Website

https://dlslab.com

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

101–250 employees

Short description

Diagnostic Laboratory Services, Inc. is the largest locally owned clinical and anatomic pathology laboratory in Hawaii, operating 50+ Patient Service Centers across Hawaii, Guam, and Saipan. It serves patients, physicians, hospitals, and employers with clinical, molecular, NGS-based, and toxicology testing services.

Ownership category

akta.pro rank

Product category

Clinical Laboratory Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Central Laboratory Services (Core Lab Operations) (HLAGAEAA)

akta.pro secondary industries

Toxicology & Therapeutic Drug Monitoring Laboratories (HLAFAMAF), Occupational Health & Employer Testing Laboratories (HLAFAMAK)

Keywords

• Clinical laboratory services
• Anatomic pathology services
• Molecular diagnostic testing
• Precision medicine testing
• Workplace drug testing

Headquarters

HQ city

Aiea

HQ country

United States

HQ region

North America

Offices10 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Laboratory Testing Services: DLS provides clinical and anatomic pathology laboratory testing services to patients with doctor's orders, healthcare providers, and hospitals. Revenue is generated through laboratory testing services billed to insurance, Medicare, Medicaid, and patients directly.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Diagnostic Laboratory Services (DLS) is a clinical and anatomic pathology laboratory that provides diagnostic testing services including clinical pathology, anatomic pathology, molecular diagnostics, microbiology, precision medicine (NGS tumor profiling, HRD testing), toxicology and drug testing, and COVID-19 testing. The company operates 50+ Patient Service Centers and partners with hospitals across Hawaii, Guam, and Saipan, serving physicians, hospital systems, employers, and patients with doctor's orders.

Product overview

Diagnostic Laboratory Services (DLS) is a comprehensive clinical and anatomic pathology laboratory offering a broad portfolio of diagnostic services and digital health tools. The core offering includes COVID-19 testing, molecular diagnostics, microbiology, toxicology/drug testing, pathology services, and a Precision Medicine Program for personalized treatment. DLS provides advanced research services including qPCR/Real-Time PCR, Sanger Sequencing, Microarray, Fragment Analysis, Nucleic Acid Extraction, Next Generation Sequencing (NGS), and Tumor Profiling for genetic and cancer analysis. Digital health tools include the myDLSchart patient portal with iOS/Android mobile apps, and the DLS MD Portal physician mobile app. The company also connects cancer patients to the ComboMATCH clinical trials program through National Cancer Institute sponsorship.

Differentiator

Problem solved

Functional benefit

Brands

• Hawaii Pathologists' Laboratory: Anatomic pathology laboratory brand operating under DLS.

Products and services

• COVID-19 Testing
• Precision Medicine Program
• Molecular Diagnostics
• Microbiology
• Toxicology / Drug Testing
• Pathology
• Next Generation Sequencing (NGS)
• Tumor Profiling
• qPCR / Real-Time PCR
• Sanger Sequencing
• Microarray
• Fragment Analysis
• Nucleic Acid Extraction
• ComboMATCH Clinical Trials
• myDLSchart Patient Portal
• DLS MD Portal

Quantifiable outcome

• Named Best Places to Work for 6 consecutive years (2021-2026) by Hawaii Business Magazine
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered core.

• Kona Community HospitalcoreStrategic or Co-development Partner · 29 June 2024DLS is the onsite laboratory operator for Kona Community Hospital as of June 29, 2024. The partnership provides comprehensive laboratory services to hospital patients and the community, with DLS opening outpatient service centers on the hospital campus.
• Kohala HospitalcoreStrategic or Co-development Partner · 29 June 2024DLS is the onsite laboratory operator for Kohala Hospital as of June 29, 2024. The partnership provides laboratory services to patients at the hospital and surrounding community.
• Samuel Mahelona Memorial HospitalcoreStrategic or Co-development Partner · 12 February 2024DLS opened a patient service center at SMMH on February 12, 2024. The hospital previously did not provide in-house laboratory services. DLS provides comprehensive testing and toxicology services at this location.
• Kaua'i Veterans Memorial HospitalcoreStrategic or Co-development Partner · 2 January 2024DLS operates hospital laboratory services onsite at KVMH in Waimea, providing comprehensive testing for infectious diseases, drugs, pathogens, genetic disorders, women's wellness, and more. The PSC lab opened January 2, 2024.
• National Cancer Institute (NCI)coreStrategic or Co-development Partner · 1 January 2024DLS participates in ComboMATCH, a national program funded and sponsored by NCI, connecting patients to clinical trials matched to their cancer's unique genetics through DLS's advanced tumor profiling capabilities.
• Friends of Cancer Research (FOCR)coreStrategic or Co-development Partner · 1 January 2024DLS was invited to participate in the FOCR HRD Harmonization project to ensure standardization in identifying Homologous Recombination Deficiency in cancer, utilizing their NGS data to assess chromosomal structural alterations.
• Hawaii Health Systems Corporation (HHSC)coreStrategic or Co-development Partner · 1 December 2023DLS partnered with HHSC to operate hospital laboratory services onsite at KVMH and SMMH facilities. This 4-year partnership signals commitment to providing quality care to the growing West Hawaii and Kauai populations.

Scale indicators6 records

Recent moves10 records

Expansion highlights5 records

Emerging players

• Guardant Health: Precision oncology company specializing in liquid biopsy and NGS-based cancer testing — comparable to DLS's NGS tumor profiling and HRD testing capability as a specialized competitor in the precision oncology segment DLS is building toward.
• NeoGenomics: Specialized oncology-focused clinical laboratory providing NGS, liquid biopsy, and pathology services to community oncologists — closely comparable to DLS's precision medicine, NGS tumor profiling, and HRD testing offerings.

Direct peers

• Quest Diagnostics: Largest U.S. clinical reference laboratory offering routine and esoteric testing with national scale, broad payer contracts, and direct physician/hospital relationships — directly comparable to DLS across the full menu of clinical, anatomic, molecular, and toxicology testing.
• Laboratory Corporation of America (Labcorp): Major U.S. clinical laboratory network providing routine, specialty, and esoteric diagnostics plus drug testing services to physicians, hospitals, and employers — directly comparable to DLS on business model, test menu breadth, and customer base.
• ARUP Laboratories: Nonprofit national reference laboratory affiliated with the University of Utah, specializing in esoteric and complex testing including molecular diagnostics, NGS, and anatomic pathology — a strong comparable for DLS's advanced precision medicine and NGS tumor profiling capabilities.
• Sonic Healthcare: International clinical pathology and radiology services group operating laboratories across the U.S. (including BioReference), Australia, and Europe — directly comparable to DLS on multi-site clinical lab operations, anatomic pathology, and employer/occupational testing.
• BioReference Laboratories: U.S. clinical and esoteric reference laboratory (now part of Sonic Healthcare) offering routine diagnostics, women's health, oncology, and urology testing — directly comparable to DLS on test menu and physician/hospital customer focus.

Broad incumbents

• Mayo Clinic Laboratories: Reference laboratory extension of Mayo Clinic offering highly specialized esoteric and rare-disease testing with national hospital and physician outreach — broadly comparable to DLS's high-complexity test menu and hospital partnership model.
• Hologic: Women's health and molecular diagnostics company with significant clinical lab and molecular testing exposure (including CT/NG and infectious disease testing) — partially comparable to DLS's molecular diagnostics and women's wellness service lines.
• Eurofins Scientific: Global testing services group operating clinical diagnostics laboratories across multiple geographies with a broad routine and specialty test menu — broadly comparable to DLS as a multi-site clinical lab operator with research and esoteric capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/DLSlab
• LinkedInlinkedin.com/company/4556486
• Instagraminstagram.com/dlslab

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diagnostic Laboratory Services